Clinical Trials

Inclusion Criteria:

- Have a histologically confirmed active CLE or SLE with cutaneous manifestations in the
form of subacute cutaneous lupus erythematosus or/and discoid/chronic cutaneous lupus
erythematosus at least 3 months and CLASI-A at least 8 or higher.

- Participant has adequate intravenous infusion access per investigator's judgement

- Willing to comply study procedures including skin punch biopsies procedures.

- Weight is greater than 40 kg and less than130 kg.

Exclusion Criteria:

- Skin disorders other than CLE or SLE.

- Active, severe lupus nephritis requiring treatment with cytotoxic agents or high-dose
steroids.

- Active severe central nervous system lupus requiring therapeutic intervention within
60 days of baseline.

- Cancer or a history of cancer within 5 years of screening except adequately resected
cutaneous basal cells, squamous cell carcinoma, or carcinoma in situ of uterine
cervix.

- Known history of a major cardiovascular or cerebrovascular event, pulmonary arterial
hypertension, pulmonary embolism within 6 months

- Have any autoimmune or inflammatory disease that would interfere with interpretation
of test results or clinical assessments.

- History of disseminated herpes zoster or disseminated herpes simplex or recurrent
localized, dermatomal herpes zoster.

- Serious infection within 60 days of baseline or an active infection treated with oral
anti-biotics within 14 days of baseline.

- Have evidence of active or latent infection of hepatitis B or C, known history of
human immunodeficient virus (HIV) infection, or infected with Mycobacterium TB without
adequately treatment

- Laboratory abnormalities meet exclusion criteria at the Screening visit. The above
information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 7/24/23. Questions regarding updates should be directed to the study team contact.